PUBLISHER: 360iResearch | PRODUCT CODE: 1579428
PUBLISHER: 360iResearch | PRODUCT CODE: 1579428
Batten Disease Market by Product, Type of Disease, Route of Administration, End-User - Global Forecast 2025-2030
The Batten Disease Market was valued at USD 54.89 million in 2023, expected to reach USD 57.61 million in 2024, and is projected to grow at a CAGR of 5.18%, to USD 78.19 million by 2030.
Batten Disease, a rare and fatal autosomal recessive neurodegenerative disorder, predominantly affects children and is caused by genetic mutations that impair the function of certain enzymes necessary for cell health. The necessity of understanding Batten Disease lies in its debilitating nature and the lack of effective treatment options, driving research efforts to develop novel therapeutic strategies. Application revolves around gene therapy, enzyme replacement therapy, and small molecule drugs. The end-use scope spans from hospitals and diagnostic centers to specialized treatment facilities focusing on neurological disorders. The market is witnessing growth due to increasing awareness, advances in genetic research, and rising funding for orphan disease research. Key factors influencing growth include technological advancements in diagnostics and therapeutics, coupled with a growing emphasis on personalized medicine approaches. Potential opportunities exist in the development of novel therapeutics and improved diagnostic tools; thus, companies should invest in R&D to explore these areas. Collaborative efforts with academic institutions and participation in clinical trials can accelerate advancements. However, the market faces limitations such as high R&D costs, limited understanding of the disease's pathophysiology, and regulatory challenges associated with orphan drugs. Another significant challenge is the small patient population, which can impede large-scale clinical trials and commercialization. Innovative areas for business growth include using CRISPR technology for gene editing, advanced biomarker-based diagnostics, and leveraging artificial intelligence for drug discovery and patient stratification. Moreover, gene therapy and personalized medicine represent promising arenas for research and innovation. The nature of the market is specialized and driven by advancements in biotechnology; hence, companies need to focus on patient-centric approaches and strategic partnerships to maximize potential benefits. Strategic recommendations include amplifying awareness through advocacy groups, engaging in collaborative research, and exploring government incentives for orphan drug development to successfully navigate this niche market.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 54.89 million |
| Estimated Year [2024] | USD 57.61 million |
| Forecast Year [2030] | USD 78.19 million |
| CAGR (%) | 5.18% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Batten Disease Market
The Batten Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Increased awareness and diagnosis of batten disease
- Rising investment in rare disease research
- Improvement in healthcare infrastructure and access
- Market Restraints
- Limited clinical trial data and regulatory challenges
- Market Opportunities
- Development of innovative therapeutics
- Advancements in genomic research and personalized medicine
- Market Challenges
- Complexity of disease and treatment development
Porter's Five Forces: A Strategic Tool for Navigating the Batten Disease Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Batten Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Batten Disease Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Batten Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Batten Disease Market
A detailed market share analysis in the Batten Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Batten Disease Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Batten Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Batten Disease Market
A strategic analysis of the Batten Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Batten Disease Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics, BioMarin Pharmaceutical Inc., Denali Therapeutics, Neurogene Inc., Novartis AG, Orchard Therapeutics, Passage Bio, Inc., Regenxbio Inc., and Teva Pharmaceuticals Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Batten Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Product, market is studied across Drugs and Gene Therapy. The Drugs is further studied across Cerliponase Alfa, Levetiracetam, and Valproic Acid.
- Based on Type of Disease, market is studied across Adult Neuronal Ceroid Lipofuscinosis, Infantile Neuronal Ceroid Lipofuscinosis, Juvenile Neuronal Ceroid Lipofuscinosis, and Late Infantile Neuronal Ceroid Lipofuscinosis.
- Based on Route of Administration, market is studied across Intravenous, Intraventricular, and Oral.
- Based on End-User, market is studied across Homecare Settings, Hospitals, Research Institutions, and Specialty Clinics.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increased awareness and diagnosis of batten disease
- 5.1.1.2. Rising investment in rare disease research
- 5.1.1.3. Improvement in healthcare infrastructure and access
- 5.1.2. Restraints
- 5.1.2.1. Limited clinical trial data and regulatory challenges
- 5.1.3. Opportunities
- 5.1.3.1. Development of innovative therapeutics
- 5.1.3.2. Advancements in genomic research and personalized medicine
- 5.1.4. Challenges
- 5.1.4.1. Complexity of disease and treatment development
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising significance of cerliponase alfa in treatment
- 5.2.2. End-User: Diverse scope of applications in hospital settings
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Batten Disease Market, by Product
- 6.1. Introduction
- 6.2. Drugs
- 6.2.1. Cerliponase Alfa
- 6.2.2. Levetiracetam
- 6.2.3. Valproic Acid
- 6.3. Gene Therapy
7. Batten Disease Market, by Type of Disease
- 7.1. Introduction
- 7.2. Adult Neuronal Ceroid Lipofuscinosis
- 7.3. Infantile Neuronal Ceroid Lipofuscinosis
- 7.4. Juvenile Neuronal Ceroid Lipofuscinosis
- 7.5. Late Infantile Neuronal Ceroid Lipofuscinosis
8. Batten Disease Market, by Route of Administration
- 8.1. Introduction
- 8.2. Intravenous
- 8.3. Intraventricular
- 8.4. Oral
9. Batten Disease Market, by End-User
- 9.1. Introduction
- 9.2. Homecare Settings
- 9.3. Hospitals
- 9.4. Research Institutions
- 9.5. Specialty Clinics
10. Americas Batten Disease Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Batten Disease Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Batten Disease Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Latus Bio, Inc. secures USD 54 million series a funding to revolutionize CNS gene therapy with precision targeting and safer dosing
- 13.3.2. University of Rochester medical center bolsters efforts in battling batten disease with USD 5.7 million NINDS funding to accelerate gene therapy trials
- 13.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Abeona Therapeutics Inc.
- 2. Alexion Pharmaceuticals Inc.
- 3. Amicus Therapeutics
- 4. BioMarin Pharmaceutical Inc.
- 5. Denali Therapeutics
- 6. Neurogene Inc.
- 7. Novartis AG
- 8. Orchard Therapeutics
- 9. Passage Bio, Inc.
- 10. Regenxbio Inc.
- 11. Teva Pharmaceuticals Industries Ltd.
LIST OF FIGURES
- FIGURE 1. BATTEN DISEASE MARKET RESEARCH PROCESS
- FIGURE 2. BATTEN DISEASE MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 17. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 22. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 23. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. BATTEN DISEASE MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. BATTEN DISEASE MARKET DYNAMICS
- TABLE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY CERLIPONASE ALFA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY VALPROIC ACID, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL BATTEN DISEASE MARKET SIZE, BY ADULT NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL BATTEN DISEASE MARKET SIZE, BY INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL BATTEN DISEASE MARKET SIZE, BY JUVENILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL BATTEN DISEASE MARKET SIZE, BY LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENTRICULAR, BY REGION, 2018-2030 (USD MILLION)
- TABLE 22. GLOBAL BATTEN DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 25. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 26. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 27. GLOBAL BATTEN DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 28. AMERICAS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 29. AMERICAS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 30. AMERICAS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 31. AMERICAS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 32. AMERICAS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 33. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 34. ARGENTINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 35. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 36. ARGENTINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 37. ARGENTINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 38. ARGENTINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 39. BRAZIL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 40. BRAZIL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 41. BRAZIL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 42. BRAZIL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 43. BRAZIL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. CANADA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 45. CANADA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 46. CANADA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 47. CANADA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 48. CANADA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 49. MEXICO BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 50. MEXICO BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 51. MEXICO BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 52. MEXICO BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 53. MEXICO BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. UNITED STATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 55. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 56. UNITED STATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 57. UNITED STATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 58. UNITED STATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 59. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 60. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 61. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 62. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 63. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 64. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 66. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 67. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 68. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 69. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 70. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. CHINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 72. CHINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 73. CHINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 74. CHINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 75. CHINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 76. INDIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 77. INDIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 78. INDIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 79. INDIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 80. INDIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. INDONESIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 82. INDONESIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 83. INDONESIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 84. INDONESIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 85. INDONESIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 86. JAPAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 87. JAPAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 88. JAPAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 89. JAPAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 90. JAPAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. MALAYSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 92. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 93. MALAYSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 94. MALAYSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 95. MALAYSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 96. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 97. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 98. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 99. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 100. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 101. SINGAPORE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 102. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 103. SINGAPORE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 104. SINGAPORE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 105. SINGAPORE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 106. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 107. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 108. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 109. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 110. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 111. TAIWAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 112. TAIWAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 113. TAIWAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 114. TAIWAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 115. TAIWAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 116. THAILAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 117. THAILAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 118. THAILAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 119. THAILAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 120. THAILAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 121. VIETNAM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 122. VIETNAM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 123. VIETNAM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 124. VIETNAM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 125. VIETNAM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 126. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 127. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 128. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 129. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 130. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 131. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 132. DENMARK BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 133. DENMARK BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 134. DENMARK BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 135. DENMARK BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 136. DENMARK BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 137. EGYPT BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 138. EGYPT BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 139. EGYPT BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 140. EGYPT BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 141. EGYPT BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 142. FINLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 143. FINLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 144. FINLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 145. FINLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 146. FINLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 147. FRANCE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 148. FRANCE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 149. FRANCE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 150. FRANCE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 151. FRANCE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 152. GERMANY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 153. GERMANY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 154. GERMANY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 155. GERMANY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 156. GERMANY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 157. ISRAEL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 158. ISRAEL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 159. ISRAEL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 160. ISRAEL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 161. ISRAEL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 162. ITALY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 163. ITALY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 164. ITALY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 165. ITALY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 166. ITALY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 167. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 168. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 169. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 170. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 171. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 172. NIGERIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 173. NIGERIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 174. NIGERIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 175. NIGERIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 176. NIGERIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 177. NORWAY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 178. NORWAY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 179. NORWAY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 180. NORWAY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 181. NORWAY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 182. POLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 183. POLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 184. POLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 185. POLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 186. POLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 187. QATAR BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 188. QATAR BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 189. QATAR BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 190. QATAR BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 191. QATAR BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 192. RUSSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 193. RUSSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 194. RUSSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 195. RUSSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 196. RUSSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 197. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 198. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 199. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 200. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 201. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 202. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 203. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 204. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 205. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 206. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 207. SPAIN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 208. SPAIN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 209. SPAIN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 210. SPAIN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 211. SPAIN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 212. SWEDEN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 213. SWEDEN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 214. SWEDEN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 215. SWEDEN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 216. SWEDEN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 217. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 218. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 219. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 220. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 221. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 222. TURKEY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 223. TURKEY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 224. TURKEY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 225. TURKEY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 226. TURKEY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 227. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 228. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 229. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 230. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 231. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 232. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 233. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 234. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
- TABLE 235. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 236. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 237. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 238. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023
